ESMO 2021
T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer
DESTINY-Breast03
ESMO 2021
T-Dxd: New treatment paradigm for patients with…
Destiny-Breast03
ESMO 2021
T-Dxd - a new standard for 2nd line HER2+ MBC
BEVERLY, WJOG971L
ESMO 2021
VGEF antibody plus TKI: the conundrum continues
MONALEESA-02:
ESMO 2021
First study to report OS benefit with CDK4/6i in first…
CheckMate-214
ESMO 2021
Long-term survival with double checkpoint-inhibition
PRISM, STAR, KEYNOTE-564
ESMO 2021
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
POSEIDON
ESMO 2021
Chemoimmunotherapy in 1st line is getting crowded
KEYNOTE-716
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of…
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
My ESMO melanoma highlights
STAMPEDE
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate…
lung ART
ESMO 2021
PORT: is the discussion really closed?
DESTINY-Breast03
ESMO 2021
DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC
KEYNOTE-355
ESMO 2021
KEYNOTE-355: Pembrolizumab A new option for TNBC
MONALEESA-02
ESMO 2021
MONALEESA-2: Long Term 1st Line significant overall…
MONALEESA-2
ESMO 2021
Remarkable improvement of overall survival with…
DESTINY-Breast03
ESMO 2021
New standard of care for HER2+ MBC
DESTINY-Breast03
ESMO 2021
T-Dxd: New treatment paradigm for patients with…
MONALEESA-2
ESMO 2021
Ribociclib in 1st line: Long follow-up time confirms OS…
KEYNOTE-355, DESTINY Breast03, MONALEESA-2
ESMO 2021
MBC significant data: T-Dxd, Pembrolizumab, Ribciclib
Carcinomatous Meningitis
ESMO 2021
Management of Carcinomatous Meningitis (CM) in breast…
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
ESMO21 highlights in metastatic and early breast cancer
DESTINY-Breast03
ESMO 2021
Becoming the standard of care for patients with HER2+…
DESTINY-Breast03
ESMO 2021
Large step forward in HER2+ MBC with T-Dxd
Monaleesa-02
ESMO 2021
Remarkable survival benefit with Ribociclib defines a…
MONALEESA-02:
ESMO 2021
First study to report OS benefit with CDK4/6i in first…
KEYNOTE-355
ESMO 2021
Finally a survival benefit in 1st line metastatic TNBC
KEYNOTE-355
ESMO 2021
Survival data confirm pembrolizumab as standard of care
DESTINY-BREAST03, DEBRAH, DESTINY-Breast12, TUXEDO-1
ESMO 2021
Great results and further research
KEYNOTE-355
ESMO 2021
A new standard of care for TNBC
KEYNOTE355, KEYNOTE-522
ESMO
Two positive trials reinforce the role of…
DESTINY-Breast03
ESMO 2021
T-DXd: Impressive results show the potential of ADC…
Destiny-Breast03
ESMO 2021
Impressive new data on the improvement of PFS with…
DESIREE
ESMO 2021
Dose escalation of everolimus in patients with…
Destiny-Breast03
ESMO 2021
T-Dxd - a new standard for 2nd line HER2+ MBC
MONALEESA-2
ESMO 2021
Ribociclib in 1st line: Lange Nachbeobachtungszeit…
DESTINY-BREAST03, KEYNOTE-355, BrightNess
ESMO 2021
Punti salienti nel carcinoma mammario metastatico e…
Destiny-Breast03
ESMO 2021
Risultati straordinari con il T-DXd in seconda linea…
DESTINY-Breast03
ESMO 2021
Krok milowy w leczeniu zaawansowanego, HER2-dodatniego…
Destiny-Breast03
ESMO 2021
Dés résultats impressionnants avec les T-DXd en 2ème…
KEYNOTE355, KEYNOTE-522
ESMO 2021
Doua trialuri pozitive in tratamentului imunoonologic…
Destiny-Breast03
ESMO 2021
T-DXd: un nuevo estándar de tratamiento en pacientes…
Monaleesa-02
ESMO 2021
Beneficiu ramarcabil cu Ribociclib in prima linie de…
DESTINY-Breast03
ESMO 2021
T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der…
KEYNOTE-355
ESMO 2021
Nareszcie wydłużenie całkowitego czasu przeżycia w 1.…
KEYNOTE-522
ESMO 2021
TNBC: CPI performing in the neo-adjuvant setting
BrighTNess
ESMO 2021
TNBC: Carboplatinum in neoadjuvant therapy
HER2+ Meta-Analyses
ESMO 2021
HER2+: Reduced duration of adjuvant Trastuzumab
KEYNOTE-522, BrighTNess
ESMO 2021
TNBC Benefit: Pembro + NACT; Carboplatinum
KEYNOTE-522
ESMO 2021
High risk patients deserve Pembro
BrighTNess
ESMO 2021
Addition of Carbo-Platin with signifcant EFS advantage
coopERA BC
ESMO 2021
Neoadjuvant Giredestrant showed anti-proliverative…
ESMO 2021
Shortening the trastuzumab therapy to 6 months?
GIM4
ESMO 2021
Extended adjuvant Letrozole with significant DFS…
BrighTNess
ESMO 2021
Carboplatin, a new standard of care in early TNBC?
HER2 - Metaanalysen
ESMO 2021
Trastuzumab + Lapatinib; reducing the duration of…
WSG ADAPT TP
ESMO 2021
Patient selection allows efficacy and deescalation
ESMO 2021
ESMO 2021
Verkürzung der Trastuzumab-Therapie auf 6 Monate?
KEYNOTE-522
ESMO 2021
Pembrolizumab - eine Option für high risk Pat.
WSG ADAPT TP
ESMO 2021
Patientenselektion mit hoher Wirksamkeit und…
HER2 - Metaanalysen
ESMO 2021
Trastuzumab: Kombination mit Lapatinib und verkürzte…
GIM4
ESMO 2021
Estensione del letrozolo adiuvante con vantaggio…
coopERA BC
ESMO 2021
Giredestrant zeigt anti-proliverative Wirkung im…
BrighTNess
ESMO 2021
Aggiunta di carboplatino neoadiuvante con vantaggio…
BrighTNess
ESMO 2021
Karboplatyna – nowy standard leczenia we wczesnym,…
BFAST
ESMO 2021
BFAST: The Challenge of new biomarkers for…
DESTINY-Lung01, TROPION, ZENITH20-4
ESMO 2021
Upcoming therapy options in oncogenic-driven NSCLC
EMPOWER-Lung 3, POSEIDON, other
ESMO 2021
IO combinations in advanced NSCLC - revolution and…
Atalante-1, MRTX-500
ESMO 2021
New options for 2nd line after IO-failure
LBA47
ESMO 2021
Are vaccines the way forward after progressing on…
BEVERLY
ESMO 2021
EGFR TKI plus VEGF inhibition
BFAST
ESMO 2021
Potential new biomarker for immunotherapy
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
New options in salvage setting for EGFR-mutant patients
DESTINY-Lung01, ZENITH20-4
ESMO 2021
HER2 mutations: new opportunities effective
EMPOWER-Lung3
ESMO 2021
Cemiplimab + chemotherapy: 1st presentation of…
DESTINY-Lung01
ESMO 2021
New opportunitiy to treat HER2-mutated lung cancer
POSEIDON
ESMO 2021
Chemoimmunotherapy in 1st line is getting crowded
MRTX-500
ESMO 2021
2nd line option after IO failure
DESTINY-Lung01
ESMO 2021
Trastuzumab Deruxtecan, a new option for HER2+ lung…
EMPOWER-Lung3
ESMO 2021
New 1st line option
BEVERLY, WJOG971L
ESMO 2021
VGEF antibody plus TKI: the conundrum continues
NVALT22
ESMO 2021
KRASG12C and platinum doublet chemotherapy: does the…
WJOG9717L study
ESMO 2021
Failure to demonstrate PFS-improvement when combining…
ESMO 2021
Gavo-cel dose escalation in refractory…
ZENITH20-4
ESMO 2021
Poziotinib in HER2 mutated lung cancer
TROPION-PanTumor01
ESMO 2021
New ADC for lung cancer
DESTINY-Lung01
ESMO 2021
A new treatment for HER2-mutated NSCLC
TROPION-PanTumor01, CHRYSALIS, CHRYSALIS-2
ESMO 2021
Nuevas terapias en linea avanzada de pacientes con…
DESTINY-Lung01
ESMO 2021
Un nouveau traitement pour le CBNPC HER2-muté
DESTINY-Lung01, ZENITH20-4
ESMO 2021
HER2 Mutation: Drug-Immuno-Conjugates effektiv
Atalante-1, MRTX-500
ESMO 2021
Nuevas opciones terapéuticas en segunda linea tras…
POSEIDON
ESMO 2021
Chemoimmuntherapie 1st line: Wohin führt POSEIDON?
TROPION-PanTumor01
ESMO 2021
Neues AWK beim Lungenkarzinom
ESMO 2021
Kein Vorteil für Anti-IL1 AK
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären…
Étude WJOG9717L
ESMO 2021
Absence d'amélioration de la SSP en associant le…
DESTINY-Lung01
ESMO 2021
le TdxD, nouvelle option pour les CBNPC HER2+?
EMPOWER-Lung3
ESMO 2021
Cemilimab + Chemotherapie: Erste Daten der…
COAST, PACIFIC-R
ESMO 2021
Stage III NSCLC - the new stage IV ?!
IMpower010, IONESCO
ESMO 2021
Immune checkpoint inhibitors - on the way to standard…
lung ART
ESMO 2021
PORT: is the discussion really closed?
DESTINY-Lung01
ESMO 2021
Potential new standard of care in NSCLC
GEMSTONE-301
ESMO 2021
Inflection point in next generation drug development
IONESCO, LCMC3
ESMO 2021
IO mono-Induction: window of opportunity to guide…
PACIFIC-R, COAST, GEMSTONE-301
ESMO 2021
Update on chemoradiation for stage III NSCLC
PACIFIC-R
ESMO 2021
Durvalumab consolidation in a real world setting
COAST
ESMO 2021
COAST on the horizon
COAST
ESMO 2021
The power of randomization
IMpower010
ESMO 2021
Completing the picture
IMpower010
ESMO 2021
Wind of change?
GEMSTONE-301
ESMO 2021
Immunotherapy improves PFS after sequential or…
IMpower010
ESMO 2021
Update on IMpower010
COAST
ESMO 2021
New option in unresectable NSCLC?
IMpower010
ESMO 2021
The benefit of adjuvant atezolizumab in PD-L1 low
IONESCO
ESMO 2021
Endpoint pathological response in induction therapy…
Atalante-1
ESMO 2021
Zijn vaccins de toekomst na progressie op…
IMpower010
ESMO 2021
Update IMpower010
COAST
ESMO 2021
nouve opzioni per lo NSCLC Stadio III inoperabile?
IONECSO
ESMO 2021
Pathological Response als Endpunkt bei…
ESMO 2021
IMpower010 Update: Stellenwert von Atezolizumab…
lung ART
ESMO 2021
Postoperatie radiotherapie bij N2 ziekte: is de…
PACIFIC-R
ESMO 2021
Quelle efficacité du durvalumab en pratique clinique?
COAST
ESMO 2021
Neue Horizonte durch COAST
ESMO 2021
Neue IO-Kombinationen vielversprechend
IONESCO, LCMC3
ESMO 2021
IO Mono Induktion - Zeitfenster für Immuntherapie
IMpower010
ESMO 2021
Learnings from IMpower010
NVALT22
ESMO 2021
KRASG12C en platinum doublet chemotherapie: maakt de…
GEMSTONE-301
ESMO 2021
L'immunothérapie améliore la SSP après une…
Checkmate 743, CASPIAN
ESMO 2021
Update on important phase III trials
CASPIAN
ESMO 2021
The tail matters even in ES-SCLC
Checkmate743, CASPIAN
ESMO 2021
Actualizaciones en estudios fase III
CASPIAN
ESMO 2021
la coda conta anche nel SCLC in malattia estesa
NIVOTHYM
ESMO 2021
NIVOTHYM: Immunotherapy for thymic tumors
NIVOTHYM
ESMO 2021
Is there a role for immunotherapy for thymic tumors?
NIVOTHYM
ESMO 2021
Quelle place de l’immunothérapie pour les tumeurs…
Checkmate 743, NCT02856425
ESMO 2021
New era in mesothelioma – stay tuned!
CheckMate 744
ESMO 2021
IO-IO, la strada da percorrere nel mesotelioma
ESMO 2021
Langzeitüberleben durch IO
Checkmate743, CASPIAN
ESMO 2021
Actualizaciones en estudios fase III
COLUMBUS, SECOMBIT
ESMO 2021
New data for BRAF-mutated melanoma patients
RELATIVITY-047
ESMO 2021
RELATIVITY-047: Subgroup updates; Enduring benefit and…
CheckMate 204, GEM1802/EBRAIN-MEL
ESMO 2021
CheckMate 204: Brain metastases - Promising…
KEYNOTE-716
ESMO 2021
KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C
MASTERKEY-265
ESMO 2021
MASTERKEY-265: Pembrolizumab +/- T-VEC
KEYNOTE-716, RELATIVITY-047, COLUMBUS
ESMO 2021
My ESMO melanoma highlights
ESMO 2021
Highlights from this year's ESMO
RELATIVITY-047
ESMO 2021
Additional efficacy and shifts in treatment options
KEYNOTE-716
ESMO 2021
New strategies for adjuvant stage II
KEYNOTE-716
ESMO 2021
Pembrolizumab is a good option for adjuvant stage IIB/C
RELATIVITY-047
ESMO 2021
LAG-3-blocking ab shows benefit in combination with…
CheckMate 204
ESMO 2021
Nivo/Ipi for brain metastatses
ESMO 2021
No preference for sequential therapy
COLUMBUS
ESMO 2021
A 5 year update
MASTERKEY-265
ESMO 2021
No significant improvement
RELATIVITY-047
ESMO 2021
Promising data, but some questions remain
KEYNOTE-716
ESMO 2021
Pembrolizumab adjuvant in stage II reduces the risk of…
CheckMate 204
ESMO 2021
T-VEC is not a convincing partner for CPI
COLUMBUS
ESMO 2021
5 year update
KEYNOTE-716
ESMO 2021
First data using immunotherapy as an adjuvant mechanism…
ESMO 2021
Sequencing - start with immunotherapy first
DONIMI
ESMO 2021
Personalized treatment for patients according to IFN-γ…
SECOMBIT
ESMO 2021
ESMO 2021: updates on the SECOMBIT study
COLUMBUS
ESMO 2021
5 Jahres Update
CheckMate 204
ESMO 2021
T-VEC überzeugt nicht als Partner für CPI
KEYNOTE-716
ESMO 2021
Pembro adj. im Stad. II verringert Rezidivrisiko, aber…
CheckMate 204
ESMO 2021
Nivo-Ipi bei Hirnmetastasen
KEYNOTE-716
ESMO 2021
Pembro gute Option adjuvant im Stad. IIB/C
ESMO 2021
Keine Präferenz bei sequenzieller Therapie
RELATIVITY-047
ESMO 2021
LAG-3-AK zeigt Benefit in Kombi mit Nivo
SECOMBIT
ESMO 2021
ESMO 2021: aggiornamenti dello studio SECOMBIT
KEYNOTE-564
ESMO 2021
PRO results support adjuvant IO efficacy, some…
PRISM/CheckMate 214
ESMO 2021
Maintaining the IO-combination with higher flexibility.
PRISM, STAR, KEYNOTE-564
ESMO 2021
ESMO highlights: Spacing out Ipi; TKI drug holidays,…
KEYNOTE-564
ESMO 2021
Quality of Life in adjuvant immunotherapy
KEYNOTE-564
ESMO 2021
Update adjuvant immunotherapy
PRISM
ESMO 2021
Dual immunotherapy update
JAVELIN-renal101
ESMO 2021
Role of cytoreductive nephrectomy in patients treated…
PRISM
ESMO 2021
Increased flexibility for side effects due to…
ESMO 2021
HIF-2α- a promising target?
CheckMate-214
ESMO 2021
Long-term survival with double checkpoint-inhibition
KEYNOTE-564
ESMO 2021
Spannende Daten, wenn auch nicht "game-changing"
CheckMate 214
ESMO 2021
Ipi mit festem Stellenwert beim aRCC
PRISM
ESMO 2021
Höhere Flexibilität bei Nebenwirkungen durch Ipilimumab
ESMO 2021
HIF-2α - una diana prometedora?
ESMO 2021
VESPER: Do we have to intensify perioperative…
ESMO 2021
NABUCCO: IPI matters – discussion on benefits in…
NORSE, VESPER
ESMO 2021
ESMO highlights: new combinations FGFRa, Pembro+sEphB4,…
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
ESMO21:The highlights of Bladder cancer
VESPER
ESMO 2021
VESPER neoadjuvant chemotherapy phase 3 trial in MIBC
VESPER
ESMO 2021
Strong signal regarding PFS and OS in ddMVAC
NABUCCO
ESMO 2021
ipilimumab-nivolumab opportunities for alternative…
IMvigor130, AURA, NABUCCO
ESMO 2021
Deciphering strategies for immunotherapy combinations
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Improving patients outcome in bladder cancer
DANUBE
ESMO 2021
PD-L1 as predictor of survival in DANUBE phase III…
NABUCCO
ESMO 2021
Ipilimumab-Nivolumab Möglichkeiten für alternative…
DANUBE
ESMO 2021
PDL-1 como predictor de supervivencia en cáncer de…
VESPER
ESMO 2021
Starkes Signal bezüglich PFS und OS bei ddMVAC
IMvigor130, AURA, NABUCCO
ESMO 2021
Descifrando las estrategias para mejorar las…
NORSE, VESPER, Phase II Pembrolizumab in combination with sEphB4-HSA (B4)
ESMO 2021
Mejorando el futuro de los pacientes con cáncer de…
VESPER, AURA, NABUCCO, NORSE
ESMO 2021
Novita’ in tema di tumori vescicali dal congresso ESMO…
ESMO 2021
STAMPEDE: Practice changing in high-risk non-metastatic…
ESMO 2021
ARCHES & PEACE-1: From doublets to triplets in mHSPC?
ESMO 2021
COSMIC-021: mCRPC perspectives in later Lines.
COSMIC-021
ESMO 2021
Hope for patients with mCRPC
STAMPEDE
ESMO 2021
The game changer: Abiraterone in high risk M0 prostate…
VESPER
ESMO 2021
DD-MVAC is the new SOC!
STAMPEDE
ESMO 2021
STAMPEDE trial: new standard of care for localized high…
PEACE-1, ARCHES
ESMO 2021
mHSPC: ADT alone is not enough!
STAMPEDE
ESMO 2021
Triplet or duplet for high-risk patients
PEACE-01
ESMO 2021
Is it really practice changing?
ARCHES
ESMO 2021
Enzalutamide added to ADT shows clear survival benefit…
STAMPEDE
ESMO 2021
New data change our practice in non-metastatic…
DS-7300
ESMO 2021
DS7300 - an exciting novel therapy in prostate cancer…
PEACE-01
ESMO 2021
Survival benefit with triplet therapy for mHSPC
PEACE-01
ESMO 2021
PEACE-1 phase 3 trial in metastatic CSPC
PEACE-01
ESMO 2021
Practice changing results for mHSCP
PRINCE
ESMO 2021
New promising Combination with Pembro and lu-PSMA
ESMO 2021
Combination therapies and new targeted therapies in…
ESMO 2021
PSMA – RLT is here!
PEACE-01
ESMO 2021
Is triplet therapy the new SOC?
ARCHES
ESMO 2021
More data for extending Enzalutamide's label for mHSPC
PEACE-1
ESMO 2021
Chemo Upront: Consider combination with Abiraterone
STAMPEDE
ESMO 2021
Significant advances in M0 PCa
PEACE-1
ESMO 2021
Chemo Upfront: Kombination mit Abiraterone bedenken!
COSMIC-021
ESMO 2021
Hoffnung für Patienten mit mCRPC
PEACE-1, ARCHES
ESMO 2021
Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η…
ARCHES
ESMO 2021
Ein weiteres Puzzlestück für Zulassungserweiterung von…
PEACE-1
ESMO 2021
PEACE-1 studien visar överlevnadsvinst med trippel…
STAMPEDE
ESMO 2021
Resultat från STAMPEDE öppnar för ny…
PRiNCE
ESMO 2021
Neue vielversprechende Kombination mit Pembro und…
ARCHES
ESMO 2021
Längre uppföljningstid I ARCHES-studien visar klar…
ESMO 2021
Kombinationsbehandlingar och nya riktade terapier vid…
STAMPEDE
ESMO 2021
Triplet oder Duplette beim hochrisiko Patienten
STAMPEDE
ESMO 2021
Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην…
ESMO 2021
CAR-T-Zell-Therapie auch bei refraktären…
ESMO 2021
Covid19 & Cancer: updates from ESMO 2021
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!